Science, research, sustainability and equality are our guiding principles and influence all areas of our work. We aim to develop effective treatments that are sustainable for both patients and the wider world.
For Gedea Biotech, sustainability is a core activity – not posturing. According to the World Health Organization (WHO), antibiotic resistance is a growing problem and one of the biggest threats to global public health. Our business concept is to create an antibiotic-free treatment for infections that works for as many people as possible. Clinical trials are currently ongoing and we are gearing up for a product launch. Everything points to pHyph having the potential to make a real impact on a market with a high medical need.
Watch the film about Gedea Biotech, the team and what we are striving for
Annette has a PhD in Medicine from Lund University and holds a Master's degree in Medical Biology from Linköping University. She has long experience of project management and business development in both listed and unlisted companies also from the healthcare sector.
+46 (0) 708 - 91 86 81
Eva has a MSc from Linköping University and has broad experience in medical marketing and project management in the healthcare sector. She has held positions in communication, marketing and sales at Pfizer, Sanofi, Studentlitteratur and within the Swedish Medical Association.
+46 (0) 709 - 36 04 20
Mahnaz has a B.Sc. in chemistry and 30 years of experience in both drugs and medical devices. Mahnaz has served as QC / QA Director in several companies and has been the Audit Leader at inspections of several external pharmaceutical and medical technology companies in Europe, China and the United States. Within Gedea, Mahnaz is responsible for the implementation and construction of the company's quality management system and for leading the company to registration according to the quality standard ISO 13485 for medical technology.
Sten has a Degree of Master of Science in Pharmacy from University of Uppsala. He has held positions as clinical trials manager and project manager for over 25 years. He has extensive experience from developing pharmaceutical products and medical devices.
Olov is Professor of Organic Chemistry at Lund University. He has extensive experience in starting and running innovative life science companies. Olov is co-founder of and Chairman of De-NovaStella AB, Board member of PULS (Life Science Partners), Respiratorius AB, Gabather AB and Glactone AB.
Helena has a PhD in medicine and a senior consultant in obstetrics and gynecology. As a medical officer, she is responsible for clinical trials and questions regarding the use of the product. Helena has many years of experience in treating vaginal infections and their complications in clinical work. She is also a partner in PULS (Partners for Development Investments in Life Science).
Sophie has a PhD in organic chemistry and works as a researcher at Lund University. She is responsible for laboratory research and formulation within Gedea. Sophie is also a partner in PULS (Partners for Development Investments in Life Science).
Ulf is Professor of Bioorganic Chemistry at Lund University, as well as a founder and member of the board of Molecular Knowledge AB. He is also a partner of PULS (Partners for Development Investments in Life Science).
Björn is a civil engineer, Industrial Engineering and Managemnt, and has long experience as an entrepreneur and business angel (nominated twice for "Connect Angel of the Year" of Connect Syd). He is a board member of several smaller companies, as well as Fast Track Capital AB, which finances the companies in Fast Track Malmö.
Kerstin Valinder Strinnholm
Kerstin is journalist from the School of Journalism at the University of Gothenburg. She has 30 years of senior management experience in international pharmaceutical companies such as AstraZeneca and Nycomed / Takeda. She works as a business development advisor and as a director of Camurus AB (publ), Corline Biomedical AB (publ), Immunicum AB (publ) and Klifo A / S.
Mats has over 30 years of experience in the marketing and licensing business in the global pharmaceutical industry. Most recently Mats worked for Astellas Pharma, where he has been the General Manager for the Nordic and Baltic countries for the past ten years. He has long experience from senior positions in Novo Nordisk, Pharmacia Corporation and Ferring International.
Per has a PhD in Medical Science and holds a Bachelor's Degree in Analytical Chemistry and Biochemistry from Lund University. As Investment Manager at Almi Invest, Per has long experience of business development and investment in start-up companies, preferably in life science. He has had several roles in pharmaceutical and biotechnology companies. Per is currently a board member of two other start-up companies in life science.
Stina has a PhD in applied biochemistry and has 40 years of experience in research, development, management and board work in Scandinavian life science companies. As an entrepreneur, Stina has worked with research, development, manufacturing and regulatory issues within Biora AB. Stina has also been Vice President of Medicon Valley Alliance and is a member of the Board of Hansa Medical AB (publ).
Game Changer Maj 2017
Crowd Awards September 2017
The Public´s award 2018
SME Instruments 2019
Fast Track to Innovation 2020